Hao Yi-qun, Chen Tong-xin, Zhu Ya-zhong, Li Qing-sheng
Immunology/Oncology Department, Shanghai Institute for Pediatric Research, Xinhua Hospital, Shanghai Second Medical University, Shanghai 200092, China.
Zhonghua Er Ke Za Zhi. 2005 Jun;43(6):438-43.
The expression of CD25, CD45RA, CD45RO on umbilical cord blood mononuclear cells (CBMCs) and CD3(+) T lymphocytes was investigated to explore the mechanism of immunosuppressive effects of intravenous immunoglobulin on neonatal immune function.
Umbilical cord blood mononuclear cells and CD3(+) T lymphocytes isolated from 8 neonates were studied. The expression of CD25, CD45RA, CD45RO on umbilical cord blood mononuclear cells (CBMCs) and CD3(+) T lymphocytes induced with various stimuli of different combinations of IVIG and phytohemagglutinin (PHA) including (1) control group, (2) PHA activation group, (3) IVIG pre-inhibition group, (4) PHA pre-activation group, (5) PHA+IVIG group was measured with four-color immunofluorescence antibodies staining-flow cytometric technique. The results were also compared with peripheral blood mononuclear cells of 8 adults (PBMCs).
IVIG inhibited the PHA-induced proliferation of CBMCs as reflected by the decreased expression of CD25 and CD45RO. The amounts of CD25(+) and CD4(+)CD45RO(+) CBMCs reached 77.52% +/- 2.31% and 64.29% +/- 3.09% after PHA use. But a decreased response in CD25(+) (7.66% +/- 1.20% and 7.78% +/- 1.46%) and CD4(+)CD45RO(+) CBMC (3.18% +/- 1.90% and 3.11% +/- 0.08%) was observed when IVIG was added in both IVIG pre-inhibition group and PHA+IVIG group. As compared with PBMCs, IVIG failed to induce the increase of the expression of CD45RA in CBMCs whereas CD45RA(+) PBMCs increased from 54.93% +/- 3.63% to 72.77% +/- 0.39% in IVIG pre-inhibition group. Moreover, IVIG inhibited the expression of CD25 and CD45RO on cord blood CD3(+) T lymphocytes no matter whether they were activated with PHA or not. The amounts of CD25(+) and CD4(+)CD45RO(+) CD3(+) T lymphocytes reached 97.92% +/- 2.19% and 80.41% +/- 5.57% after PHA use. But a decreased response in CD25(+) CBMCs (77.29% +/- 0.63%, 51.48% +/- 1.85% and 62.73% +/- 1.24%) and CD4(+)CD45RO(+) CD3(+) T lymphocytes (35.47% +/- 2.55%, 40.14% +/- 1.16% and 36.41% +/- 2.96%) was observed when IVIG was added in IVIG pre-inhibition group, PHA pre-activation group and PHA+IVIG group, and the degree of inhibition of IVIG on cord blood CD3(+) T lymphocytes was much lower than that of CBMCs.
Cord blood T lymphocytes activation was inhibited by IVIG through the inhibition of CD25(+) CBMCs expression and the prevention of transformation from CD4(+)CD45RA(+) cells into CD4(+)CD45RO(+) cells. This IVIG-mediated suppression of activation in cord blood T cells may be derived from the indirect effect of other immune cells or molecules other than the direct effects on T cells. IVIG failed to induce the increase of expression of CD45RA in CBMCs, which may be related to the fact that majority of CBMCs were CD45RA(+) cells, but this may not rule out that the immunosuppressive effect of IVIG could be accomplished by the increase of CD45RA(+) cells in adult peripheral blood mononuclear cells. The suppressive effect of IVIG on CD4(+)CD45RO(+) T lymphocytes may account for its inhibitory effect on immunoglobulin production of neonates' B cells. Considering that naïve CD45RA(+) cells dominate in neonates and IVIG can inhibit transformation from CD4(+)CD45RA(+) cells into CD4(+)CD45RO(+) cells, it is recommended that IVIG should be used properly in neonates, otherwise it may deteriorate their poor immune function especially when it is used for prophylaxis or as a treatment of neonatal non-infectious diseases, and its immunosuppressive action will increase the susceptibility of neonates to infection.
研究脐血单个核细胞(CBMCs)和CD3(+) T淋巴细胞上CD25、CD45RA、CD45RO的表达,以探讨静脉注射免疫球蛋白对新生儿免疫功能免疫抑制作用的机制。
研究从8例新生儿分离出的脐血单个核细胞和CD3(+) T淋巴细胞。采用四色免疫荧光抗体染色-流式细胞术检测不同组合的静脉注射免疫球蛋白(IVIG)和植物血凝素(PHA)刺激诱导的脐血单个核细胞(CBMCs)和CD3(+) T淋巴细胞上CD25、CD45RA、CD45RO的表达,包括(1)对照组,(2)PHA激活组,(3)IVIG预抑制组,(4)PHA预激活组,(5)PHA+IVIG组。结果还与8例成年人的外周血单个核细胞(PBMCs)进行了比较。
IVIG抑制了PHA诱导的CBMCs增殖,表现为CD25和CD45RO表达降低。使用PHA后,CD25(+)和CD4(+)CD45RO(+) CBMCs的比例分别达到77.52%±2.31%和64.29%±3.09%。但在IVIG预抑制组和PHA+IVIG组中加入IVIG后,观察到CD25(+)(7.66%±1.20%和7.78%±1.46%)和CD4(+)CD45RO(+) CBMC(3.18%±1.90%和3.11%±0.08%)的反应降低。与PBMCs相比,IVIG未能诱导CBMCs中CD45RA表达增加,而在IVIG预抑制组中,CD45RA(+) PBMCs从54.93%±3.63%增加到72.77%±0.39%。此外,无论是否用PHA激活,IVIG均抑制脐血CD3(+) T淋巴细胞上CD25和CD45RO的表达。使用PHA后,CD25(+)和CD4(+)CD45RO(+) CD3(+) T淋巴细胞的比例分别达到97.92%±2.19%和80.41%±5.57%。但在IVIG预抑制组、PHA预激活组和PHA+IVIG组中加入IVIG后,观察到CD25(+) CBMCs(77.29%±0.63%、51.48%±1.85%和62.73%±1.24%)和CD4(+)CD45RO(+) CD3(+) T淋巴细胞(35.47%±2.55%、40.14%±1.16%和3,6.41%±2.96%)的反应降低,且IVIG对脐血CD3(+) T淋巴细胞的抑制程度远低于对CBMCs的抑制程度。
IVIG通过抑制CD25(+) CBMCs表达以及阻止CD4(+)CD45RA(+)细胞向CD4(+)CD45RO(+)细胞转化来抑制脐血T淋巴细胞活化。IVIG介导的脐血T细胞活化抑制可能源于对T细胞的直接作用之外的其他免疫细胞或分子的间接作用。IVIG未能诱导CBMCs中CD45RA表达增加,这可能与大多数CBMCs是CD45RA(+)细胞这一事实有关,但这并不排除IVIG的免疫抑制作用可通过增加成人外周血单个核细胞中CD45RA(+)细胞来实现。IVIG对CD4(+)CD45RO(+) T淋巴细胞的抑制作用可能解释了其对新生儿B细胞免疫球蛋白产生的抑制作用。鉴于新生儿中初始CD45RA(+)细胞占主导且IVIG可抑制CD4(+)CD45RA(+)细胞向CD4(+)CD45RO(+)细胞转化,建议在新生儿中合理使用IVIG,否则可能会使其原本较差的免疫功能恶化,尤其是在用于预防或治疗新生儿非感染性疾病时,其免疫抑制作用会增加新生儿感染的易感性。